Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1179

1.

Unveiling the important roles of coexisting contaminants on photochemical transformations of pharmaceuticals: Fibrate drugs as a case study.

Zhang YN, Zhou Y, Qu J, Chen J, Zhao J, Lu Y, Li C, Xie Q, Peijnenburg WJGM.

J Hazard Mater. 2018 Jun 30;358:216-221. doi: 10.1016/j.jhazmat.2018.06.068. [Epub ahead of print]

PMID:
29990809
2.

Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner.

Cizkova K.

Toxicol Appl Pharmacol. 2018 Jun 27;355:156-163. doi: 10.1016/j.taap.2018.06.025. [Epub ahead of print]

PMID:
29960002
3.

Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials.

Sahebkar A, Simental-Mendía LE, Pirro M, Montecucco F, Carbone F, Banach M, Barreto GE, Butler AE.

Ann Med. 2018 Jun 29:1-22. doi: 10.1080/07853890.2018.1495338. [Epub ahead of print]

PMID:
29957074
4.

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar R, Wong KA, Liu CH, Bowlus CL.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.

5.

Identifying suspected familial chylomicronemia syndrome.

Rengarajan R, McCullough PA, Chowdhury A, Tecson KM.

Proc (Bayl Univ Med Cent). 2018 May 21;31(3):284-288. doi: 10.1080/08998280.2018.1463784. eCollection 2018 Jul.

6.

Diabetes and lipid metabolism.

Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis A.

Hormones (Athens). 2018 Mar;17(1):61-67. doi: 10.1007/s42000-018-0014-8. Epub 2018 Apr 16. Review.

7.

Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver.

Hedrington MS, Davis SN.

Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):671-677. doi: 10.1080/17425255.2018.1483337. Epub 2018 Jun 7. Review.

PMID:
29847748
8.

Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects?

Cartolano FC, Pappiani C, Freitas MCP, Figueiredo Neto AM, Carioca AAF, Damasceno NRT.

Arq Bras Cardiol. 2018 Apr;110(4):339-347. doi: 10.5935/abc.20180054. Portuguese, English.

9.

Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies.

Ugwu DI, Okoro UC, Mishra NK, Okafor SN.

Lipids Health Dis. 2018 May 22;17(1):120. doi: 10.1186/s12944-018-0764-y.

10.

Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report.

Dalugama C, Pathirage M, Kularatne SAM.

J Med Case Rep. 2018 May 22;12(1):143. doi: 10.1186/s13256-018-1685-0.

11.

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Sniderman AD, Couture P, Martin SS, DeGraaf J, Lawler PR, Cromwell WC, Wilkins JT, Thanassoulis G.

J Lipid Res. 2018 Jul;59(7):1266-1275. doi: 10.1194/jlr.R082271. Epub 2018 May 16.

PMID:
29769239
12.

Anticancer Properties of Fenofibrate: A Repurposing Use.

Lian X, Wang G, Zhou H, Zheng Z, Fu Y, Cai L.

J Cancer. 2018 Apr 6;9(9):1527-1537. doi: 10.7150/jca.24488. eCollection 2018. Review.

13.

The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy.

Polnak JF, Delate T, Clark NP.

J Thromb Thrombolysis. 2018 Apr 21. doi: 10.1007/s11239-018-1664-8. [Epub ahead of print]

PMID:
29681002
14.

The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study.

Shi R, Zhao L, Qi Y.

BMC Ophthalmol. 2018 Apr 18;18(1):100. doi: 10.1186/s12886-018-0769-3.

15.

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.

Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group.

J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7.

16.

Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions.

Dou XZ, Nath D, Shin Y, Ma JX, Duerfeldt AS.

Bioorg Med Chem Lett. 2018 Apr 5. pii: S0960-894X(18)30189-6. doi: 10.1016/j.bmcl.2018.03.010. [Epub ahead of print]

PMID:
29628329
17.

Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.

Yamamoto Y, Takei K, Arulmozhiraja S, Sladek V, Matsuo N, Han SI, Matsuzaka T, Sekiya M, Tokiwa T, Shoji M, Shigeta Y, Nakagawa Y, Tokiwa H, Shimano H.

Biochem Biophys Res Commun. 2018 May 5;499(2):239-245. doi: 10.1016/j.bbrc.2018.03.135. Epub 2018 Mar 22.

PMID:
29567478
18.

Safety of high-dose daptomycin in patients with severe renal impairment.

Tai CH, Shao CH, Chen CY, Lin SW, Wu CC.

Ther Clin Risk Manag. 2018 Mar 13;14:493-499. doi: 10.2147/TCRM.S159587. eCollection 2018.

19.

Evaluation of a new equation for LDL-c estimation and prediction of death by cardiovascular related events in a German population-based study cohort.

Mendes de Cordova CM, de Santa Helena ET, Galgowski C, Figueira VH, Setter GB, Markus MRP, Schmidt CO, Völzke H, Ittermann T.

Scand J Clin Lab Invest. 2018 May;78(3):187-196. doi: 10.1080/00365513.2018.1432070. Epub 2018 Mar 8.

PMID:
29517392
20.

The therapeutic potential of CETP inhibitors: a patent review.

Wang X, Li W, Hao L, Xie H, Hao C, Liu C, Li W, Xiong X, Zhao D.

Expert Opin Ther Pat. 2018 Apr;28(4):331-340. doi: 10.1080/13543776.2018.1439476. Epub 2018 Feb 15. Review.

PMID:
29424255

Supplemental Content

Loading ...
Support Center